provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content

Aduhelm

aducanumab
Used for Alzheimer's Disease
Used for Alzheimer's Disease

Aduhelm (aducanumab or aducanumab-avwa) is an anti-amyloid monoclonal antibody. It's used to treat mild Alzheimer’s disease in adults. Aduhelm (aducanumab) is given as a monthly infusion through the veins by a healthcare professional (HCP). Some side effects of this medication include headaches and confusion. Aduhelm (aducanumab) received FDA approval in 2021 under the accelerated approval process. But the manufacturer of Aduhelm (aducanumab) announced that they plan to discontinue Aduhelm (aducanumab) in the United States in 2024.

Reviewed by:
reviewer
Allison Gourley, PharmD
reviewer
Kristianne Hannemann, PharmD
Last reviewed on April 24, 2024
BasicsSide effectsPros & consPharmacist tipsFAQsWarningsDosageAlternativesLatest newsReferencesPricesMedicare
basics-icon

What is Aduhelm (aducanumab)?

What is Aduhelm (aducanumab) used for?

How Aduhelm (aducanumab) works

Aduhelm (aducanumab) is anti-amyloid monoclonal antibody. It specifically targets a protein in the brain called beta-amyloid. In Alzheimer’s disease, these proteins clump together to form plaques.

Aduhelm (aducanumab) lowers the amount of beta-amyloid plaques in the brain. This suggests, but doesn't show, Aduhelm (aducanumab) can help slow Alzheimer’s from getting worse. More studies are needed to confirm whether or not fewer plaques actually means slower disease progression.

Drug Facts

Common BrandsAduhelm
Drug ClassAmyloid beta-directed antibody
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
basics-icon

What are the side effects of Aduhelm (aducanumab)?

The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.

Common Side Effects

  • Swelling in the brain (35%)
  • Headache (21%)
  • Small brain bleed (19%)
  • Deposits in the brain due to bleeding that can cause hearing loss or gait and balance issues (ARIA-H superficial siderosis, 15%)
  • Falling (15%)
  • Diarrhea (9%)
  • Confusion (8%)

Serious Side Effects

Contact your healthcare provider immediately if you experience any of the following.
  • Brain swelling or bleeding: headache, dizziness, nausea, confusion, or vision changes
  • Allergic reaction: hives (urticaria) or swelling of the lips, mouth, and throat

Source: DailyMed

More on Aduhelm (aducanumab) side effects

Health: Aduhelm: man in bed headache 914768030

6 Aduhelm Side Effects You Should Know About

Written by Connie Zheng, PharmD
pros-and-cons

Pros and cons of Aduhelm (aducanumab)

thumbs-up

Pros

Lowers the amount of amyloid beta plaques that build up in the brain

Given once every 4 weeks

Not many known interactions with other medications

thumbs-down

Cons

Unclear if Aduhelm (aducanumab) can slow down Alzheimer's from getting worse

Given as an IV infusion by a healthcare professional

Requires MRIs (brain scans) before and during treatment

pharmacist-tips

Pharmacist tips for Aduhelm (aducanumab)

pharmacist

  • A healthcare professional (HCP) will need to administer Aduhelm (aducanumab). Typically, you'll have to go into your prescriber's office or a clinic every 4 weeks for the infusion. If you can't make the appointment, call your HCP's office right away to reschedule or talk about next-steps.

    • Aduhelm (aducanumab) can cause amyloid-related imaging abnormalities (ARIA). These are common side effects that might not always cause symptoms, but can be serious. Call your HCP right away if you experience symptoms of ARIA, such as headaches, dizziness, nausea, confusion, or vision changes.

      • You'll need to get an MRI brain scan before starting Aduhelm (aducanumab) and before the 5th, 7th, 9th, and 12th dose. This is to check for swelling (ARIA-E) or bleeding (ARIA-H) in the brain.

        faqs

        Frequently asked questions about Aduhelm (aducanumab)

        Why is Aduhelm (aducanumab) being discontinued?
        The makers of Aduhelm (aducanumab) decided to discontinue it in order to focus more on developing other treatments for Alzheimer’s disease.
        Is Aduhelm (aducanumab) still available?
        Aduhelm (aducanumab) might still be available, but not for long because the manufacturer decided to stop making this medication. If you were receiving Aduhelm (aducanumab) as part of a clinical trial, you might still get doses until early May of 2024; others receiving it by prescription might be able to get doses until early November of 2024. Have a discussion with your care team about what this means for your treatment plan. Ask your care team about other treatment options for Alzheimer’s disease that might be appropriate for you.
        When was Aduhelm (aducanumab) approved?
        Aduhelm (aducanumab) received accelerated approval in June of 2021. But in 2024, makers of Aduhelm (aducanumab) announced they were going to discontinue Aduhelm (aducanumab).
        Does Aduhelm (aducanumab) cure Alzheimer's?
        No, Aduhelm (aducanumab) doesn't cure Alzheimer's disease. There's currently no known cure for Alzheimer's disease. But there are lifestyle and medication treatment options that might slow down the worsening of symptoms. Talk with your healthcare team if you have questions about Aduhelm (aducanumab) and Alzheimer's disease.
        Can Aduhelm (aducanumab) slow down Alzheimer's?
        There isn't enough information to understand whether Aduhelm (aducanumab) can slow down Alzheimer’s from getting worse. The FDA gave Aduhelm (aducanumab) accelerated approval based on findings that it lowers the amount of amyloid beta plaques that builds up in the brain. The findings suggest that Aduhelm (aducanumab) might slow down Alzheimer's disease. Additional studies are needed to confirm the benefits of treatment.
        How is Aduhelm (aducanumab) administered?
        Aduhelm (aducanumab) is given by IV infusion through a needle placed in your arm. It will take about 1 hour to complete each dose.
        How is Leqembi (lecanemab) different from Aduhelm (aducanumab)?
        Both Leqembi (lecanemab) and Aduhelm (aducanumab) are monoclonal antibodies that target beta-amyloid in the brain. Both are given as infusions through the veins. But Leqembi is infused once every 2 weeks, whereas Aduhelm is given every 4 weeks. Early research suggests that Leqembi can slow down the worsening of Alzheimer's disease. But research results for Aduhelm weren't so clear. The manufacturer of Aduhelm will stop making this medication in 2024; Leqembi will be the only anti-amyloid therapy available at that time. Talk with your healthcare team if you have more questions about either medications.
        What are ARIA side effects of Aduhelm (aducanumab)?
        ARIA stands for amyloid-related imaging abnormalities. These are irregular changes in the brain, such as small brain bleeds or brain swelling. ARIA typically don't cause any symptoms, and are usually only found through magnetic resonance imaging (MRI) brain scans. But sometimes, ARIA can cause headaches, dizziness, or confusion. If you receive Aduhelm (aducanumab), your healthcare team will ask you to get brain scans regularly to check for ARIA. If they find ARIA, they might ask you to pause or stop Aduhelm (aducanumab), depending on how the brain scans look and whether you experience symptoms.
        GoodRxEducationalIcon

        How to save using GoodRx

        Compare Prices
        1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
        Select your free coupon
        2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
        Show coupon to your pharmacist
        3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
        Get free couponLearn more
        warings-icon

        What are the risks and warnings for Aduhelm (aducanumab)?

        Aduhelm (aducanumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.

        risk-warning

        Amyloid related imaging abnormalities (ARIA)

        • Risk factors: Being a carrier of the apolipoprotein E ε4 (ApoE ε4) gene

          Aduhelm (aducanumab) can cause serious issues that show up on brain images (MRIs), though you might not feel symptoms. This includes brain swelling (ARIA-edema or ARIA-E) and brain bleeding (ARIA-hemosiderin deposition or ARIA-H). Before starting Aduhelm (aducanumab), you'll need a recent MRI from within the last year.

          Brain swelling (ARIA-E) was more commonly seen in people who have the ApoE ε4 gene. Swelling was most likely to occur early in treatment within the first 8 doses. The majority of brain swelling cases went away after about 20 weeks.

          In studies, about 10% of people who took Aduhelm (aducanumab) had symptoms due to ARIA. The most common symptoms are headache, confusion, dizziness, vision changes, and nausea. You'll likely need an MRI if you experience any of these symptoms. If you don't have symptoms, you'll still need MRIs before the 5th, 7th, 9th, and 12th dose as part of the regular monitoring needed while taking this medication. Depending on the severity of MRI scans, your prescriber might decide to temporarily pause, completely stop, or carefully continue your medication.

          risk-warning

          Allergic reactions

          Aduhelm (aducanumab) can cause an allergic reaction in some people. You might get hives or feel your lips, mouth, and throat swell up which can make it difficult to breath. Let your healthcare team know right away so they can stop the infusion and give you the appropriate treatment.

          dosage

          Aduhelm (aducanumab) dosage forms

          Typical dosing for Aduhelm (aducanumab)

          Aduhelm (aducanumab) is an intravenous (IV, into the veins) infusion that is administered by a healthcare professional (HCP) every 4 weeks. It takes about 1 hour to give the full dose of the medication. Doses are based on your body weight and your HCP will determine the appropriate dose for you each time.

          The typical starting dose is 1 mg/kg. The dose is slowly raised over 6 months to the recommended maintenance dose of 10 mg/kg.

          • Doses 1 and 2: 1 mg/kg

          • Doses 3 and 4: 3 mg/kg

          • Doses 5 and 6: 6 mg/kg

          • Doses 7 and beyond: 10 mg/kg (maintenance dose)

          alternatives

          What are alternatives to Aduhelm (aducanumab)?

          There are a number of medications that your doctor can prescribe in place of Aduhelm (aducanumab). Compare a few possible alternatives below.
          Aduhelm (aducanumab)
          Used for:
          View Prices
          Leqembi (lecanemab)
          Used for:

          • Alzheimer’s disease (mild cognitive impairment)

          View Prices
          Memantine (Nameda)
          Used for:
          $12.90 Lowest GoodRx priceView Prices

          Get savings updates for Aduhelm (aducanumab)

          Receive price alerts, news, and other messages from GoodRx about Aduhelm (aducanumab) and other healthcare topics and relevant savings offers.

          By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

          References

          Best studies we found

          Alzheimer’s Association. (n.d.). Aducanumab to be discontinued as an Alzheimer’s treatment.

          Biogen Inc. (2023). Aduhelm- aducanumab injection, solution [package insert]. DailyMed.

          Biogen Inc. (2024). Biogen to realign resources for Alzheimer's disease franchise. Globe Newswire.

          View All References (3)

          National Institute on Aging. (2024). What happens to the brain in Alzheimer’s disease?

          U.S. Food and Drug Administration. (2021). FDA’s decision to approve new treatment for Alzheimer’s disease.

          U.S. Food and Drug Administration. (2024). Accelerated approval program.

          GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.
          Was this page helpful?

          Browse medications

          View All

          Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.